Testing medicines to treat children with pulmonary arterial hypertension(PAH)
A randomized, open label study comparing safety and efficacyparameters for a high and a low dose of ambrisentan (adjustedfor body weight) for the treatment of pulmonary arterialhypertension in paediatric patients aged 8 years up to 18 years. - Efficacy and Safety of Ambrisentan in Children 8-17yrs A randomized, open label study comparing safety and efficacyparameters for a high and a low dose of ...